Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital Changes
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioNexus Gene Lab (BGLC) Change in Receivables (2019 - 2025)

Historic Change in Receivables for BioNexus Gene Lab (BGLC) over the last 7 years, with Q3 2025 value amounting to -$206475.0.

  • BioNexus Gene Lab's Change in Receivables fell 3470.53% to -$206475.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $460258.0, marking a year-over-year decrease of 5424.14%. This contributed to the annual value of $147760.0 for FY2024, which is 7729.6% down from last year.
  • According to the latest figures from Q3 2025, BioNexus Gene Lab's Change in Receivables is -$206475.0, which was down 3470.53% from $480950.0 recorded in Q2 2025.
  • In the past 5 years, BioNexus Gene Lab's Change in Receivables ranged from a high of $1.2 million in Q4 2022 and a low of -$402845.0 during Q1 2021
  • Over the past 5 years, BioNexus Gene Lab's median Change in Receivables value was -$112473.0 (recorded in 2024), while the average stood at $109383.8.
  • Per our database at Business Quant, BioNexus Gene Lab's Change in Receivables crashed by 34595.06% in 2021 and then skyrocketed by 71302.59% in 2024.
  • Quarter analysis of 5 years shows BioNexus Gene Lab's Change in Receivables stood at $777770.0 in 2021, then skyrocketed by 51.34% to $1.2 million in 2022, then decreased by 1.75% to $1.2 million in 2023, then crashed by 74.2% to $298398.0 in 2024, then plummeted by 169.19% to -$206475.0 in 2025.
  • Its last three reported values are -$206475.0 in Q3 2025, $480950.0 for Q2 2025, and -$112615.0 during Q1 2025.